An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG®-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma To assess the pharmacokinetic profile of EndoTAG-1 (22mg/m²) after single-dose and in steady-state

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients Primary objective is to assess the efficacy of EndoTAG-1 + paclitaxel (combination therapy) and EndoTAG-1 (monotherapy) as a rescue therapy for patients with triple receptor negative relapsed or metas...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Safety Objectives: - Assessment of the safety of biweekly infusions of EndoTAG™-1 and weekly infusions of gemcitabine via: - Incidence and percentage with patients EndoTAG™-1 and gemcitabine relat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

EndoTAG®-1 and Gemcitabine Combination Therapy for the Treatment of Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Not provided at time of registration

• Pays Aucun
• Organes Aucun
• Spécialités Aucune